GlassScriptPhysician profile
Leigh A Fleury
NPI 1942590450
$3,439.20
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $790 · 2022: $1,058 · 2023: $1,283 · 2024: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,085.12 | 2021-2024 | |
| Novo Nordisk INC | $361.54 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $284.91 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $200.62 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $137.29 | 2021-2023 | |
| Almatica Pharma LLC | $125.48 | 2021-2023 | Loreev Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.30 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $107.54 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $100.28 | 2022-2024 | |
| Amarin Pharma, INC. | $84.76 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $77.42 | 2021-2023 | Livalo |
| Glaxosmithkline, LLC. | $65.77 | 2021-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $61.78 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $54.15 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $54.12 | 2021-2023 | Rexulti |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Fleury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.